Skip to content
Conference Open access

Predicting breast cancer recurrence using multimodal deep learning and MRI: Systematic review

2026 · EPJ Web of Conferences · Vol 381, pp. 00010 · 0 citations · 13 references

TL;DR

This paper presents a systematic review of deep learning approaches for predicting breast cancer recurrence from multimodal Magnetic Resonance Imaging and clinicopathological data, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines.

Abstract

Breast cancer is one of the most common cancers in women worldwide affecting approximately 2.3 million women annually and causing 685,000 deaths each year. Thanks to screening and treatment, the 5-year survival rate exceeds 90% when detected early. However, recurrence remains a major challenge, occurring in 20-30% of cases often 2–5 years after initial diagnosis. Current methods (physical examinations, mammograms, clinical scores) often miss subtle signals, highlighting the urgent need for reliable, non-invasive risk stratification tools. This paper presents a systematic review of deep learning approaches for predicting breast cancer recurrence from multimodal Magnetic Resonance Imaging (MRI) and clinicopathological data, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eight studies published between 2021 and 2025 were included. Emerging trends include three-dimensional (3D) volumetric fusion networks, transformer-based temporal modeling, and radiogenomic correlation with Oncotype DX. Key challenges include heterogeneity in MRI acquisition protocols, scarcity of annotated longitudinal datasets, and insufficient model interpretability. This review maps current methodological trends, identifies research gaps, and provides a structured roadmap for clinical deployment.

Read PDF

Similar papers

Sep 2026

Breast Cancer Recurrence Status Assessment in 5 Years Using Multimodal Integrated Learning: A Feasibility Study.

The findings underscore the potential of the proposed multimodal deep learning framework to provide accessible, accurate, and generalizable recurrence risk prediction using routinely available clinical data, potentially supporting more informed treatment decisions and personalized post-treatment monitoring in real-worl...

R. Chang, Hsiang-Wei Huang, Szu-Yen Kuo et al. · 0 citations
Review Open access Sep 2026

Deep Learning Methods for Breast Cancer Detection, Classification, and Segmentation Using MRI Scans: A Systematic Review

This systematic review synthesises peer-reviewed studies published between 2014 and 2025 that exclusively applied DL techniques to breast MRI for cancer classification, prediction, or segmentation and demonstrates that DL models consistently achieve high diagnostic performance and have the potential to enhance radiolog...

Qais Al-Azzam, W. Balachandran, Ziad Hunaiti · 0 citations
#diffusion models Open access Sep 2026

Deep learning radiomics based on preoperative multiparametric MRI in predicting breast cancer recurrence risk

The DLRC model effectively predicted and stratified breast cancer recurrence risk by integrating deep learning, radiomics, and clinicopathological features and achieved the best performance in the training and internal validation sets.

Xin-Miao Gong, Ke-Pei Xu, Mei-Qi Hua et al. · 0 citations
Review

Current Medical Imaging

Liu-Ping Zhu, Ying-Jie Shao, Wen-Dong Gu et al. · 0 citations
#explainable ai Review Open access Sep 2026

Artificial intelligence in breast cancer imaging: a systematic review of detection, segmentation, explainability, and clinical translation

Artificial intelligence shows substantial potential to enhance breast cancer imaging, but broader clinical translation requires robust external and prospective validation, improved calibration, assessment of generalizability and bias, and integration into clinical workflows.

I. Khan, Syed Taimoor Hussain Shah, Alexandra Tsipourakis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.